Alembic gets final approval for Binimetinib

Alembic Pharmaceuticals Limited (NSE: APLLTD) has received final USFDA approval for generic Binimetinib tablets in 15 mg and 45 mg strengths. The product has an estimated US reference market of US$282 million for the 12 months ended September 2026. Alembic is eligible for 180 days of generic exclusivity and is the sole first applicant for the 45 mg strength. This is positive for Alembic's US generics business. The specialised oncology product provides an early-entry opportunity and could support revenue growth and profitability. However, US$282 million is the reference market, not Alembic's expected revenue. Actual earnings will depend on launch timing, market share, pricing and margins. The company has not disclosed expected sales or product-level profitability. The final approval also needs to be viewed in context: tentative approvals were already announced earlier in 2026. The next important development is commercial launch, not simply the regulatory approval. What to watch: 1. Commercial launch and initial sales. 2. US generics revenue growth and operating margins. 3. Evidence of sustained product contribution after the initial exclusivity period. View: very positive. The approval is a positive business development,